Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national blog main
rare disease drugs
4
×
boston blog main
boston top stories
san francisco blog main
biotech ipos
boston
dyne therapeutics
medical device
multiple myeloma
myotonic dystrophy type 1
national top stories
new york blog main
orbimed
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san francisco top stories
abbvie
actavalon
acute migrane
acute myeloid leukemia
aileron therapeutics
aprea therapeutics
arimoclomol
arnold levine
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bain capital
baker brothers
bausch health
bluebird bio
boehringer ingelheim
breast cancer
cancer
What
ipo
4
×
drug
company
developing
dyne
genetic
ipos
medicines
muscle
rare
therapeutics
activity
ago
biotech
biotechs
blood
brings
broader
cancer
companies
considering
data
days
detect
diseases
disorders
dog
dyne’s
early
expected
experimental
eyes
files
firm
firms
grail
hasn’t
having
humans
intended
Language
unset
Current search:
ipo
×
" rare disease drugs "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
